Survodutide

Evidence in perspective

The phase II obesity trial supplies a controlled efficacy signal, but escalation and follow-up define its scope. A later linked correction still requires full-text reconciliation. Weight-loss findings cannot stand in for separate liver-disease outcomes.

Who was studied

Adults aged 18–75 with BMI at least 27, without diabetes, in a phase 2 trial.

What the sources found

The study assessed weight change after 46 weeks, including a 20-week escalation period.

What remains unknown

Trial arms and maintenance doses cannot be treated as interchangeable starting doses; this snapshot is not a complete development or approval review. A linked 2025 correction was identified. Its full content was not accessible in the retrieved record, so the affected details remain under review.

How it works

Combines glucagon and GLP-1 receptor activity.

Combines glucagon and GLP-1 receptor activity. Trial arms and maintenance doses cannot be treated as interchangeable starting doses; this snapshot is not a complete development or approval review.

Human trials

This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.

Understanding the evidence

Reported adverse effects

• Consult the primary study for adverse-event reporting. This snapshot does not establish safety.